Last Updated on July 29, 2021 by Nancy Carteron, MD, FACR
In a healthy person, initial CMV infection often occurs without symptoms and is rarely noticed.
Most people who have CMV have no symptoms.
If a person receives a transfusion of blood containing CMV, fever and sometimes liver inflammation may develop 2 to 4 weeks later.
When CMV symptoms do appear, they may include:
Occasionally, a first-time infection with CMV may cause a mild illness called mononucleosis. Symptoms include swollen glands, liver, and spleen; fever; increased white blood cells; headache; fatigue; and sore throat.
About 8 percent of all mononucleosis cases are due to CMV infection.
- Swollen glands, fatigue, fever, and general weakness
- Irritations of the digestive tract, nausea, diarrhea
- Jaundice (yellowing of the skin or eyes)
STI Masterclass: Breaking Through the Fear, Shame, and Stigma of an STI Diagnosis
If you’re fed up with feeling unworthy, less-than, damaged, or limited by your STI, then join the next cohort in the 60-Day Masterclass, and leave feeling empowered, knowledgable, and confident again!
Click Here to Learn More
Symptoms in people with compromised immunity:
If a person with a severely weakened immune system contracts CMV, the infection may be severe, sometimes resulting in serious disease or death.
These illnesses include pneumonia and inflammations of the liver (hepatitis), brain (encephalitis), esophagus (esophagitis), large intestine (colitis), and retina of the eye (retinitis).
In people with AIDS, CMV infection is a common viral complication.
The virus also tends to infect the retina of the eye. This infection (CMV retinitis) can cause blindness.
Infection of the brain (encephalitis), pneumonia, or painful ulcers of the intestine or esophagus may also develop.
Some symptoms may include:
- Visual impairment and blindness
- Pneumonia
- Diarrhea
- Ulcers in the digestive tract, possibly causing bleeding
- Hepatitis
- Inflammation of the brain (encephalitis)
- Behavioral changes
- Seizures
- Coma
Symptoms in babies with congenital CMV:
If a pregnant person transmits CMV to the fetus, miscarriage, stillbirth, or death of the newborn may result.
Babies who contract CMV during birth rarely develop any illness from these infections.
Infants born prematurely who contract CMV during birth have a greater chance of complications, including pneumonia, hepatitis, decreased blood platelets. Death is caused by bleeding, anemia, or extensive damage to the liver or brain. Newborns who survive may have hearing loss and intellectual disability.
However, an unborn baby is at great risk for serious problems when the mother becomes infected with CMV for the first time while pregnant.
About 10 percent of these babies will be born with obvious problems, including prematurity, lung problems, an enlarged liver and spleen, jaundice, anemia, low birth weight, small head size, and inflammation of the retina. About 90 percent of these babies may appear perfectly normal at birth. Unfortunately, about 20 percent later develop severe hearing impairments and mental disability.
A 2003 report found that pregnant people 25 years of age and older who are immune to CMV are much less likely to pass the virus to their babies than younger people who have never been exposed to CMV.
Some symptoms may include:
- Yellow skin and eyes (jaundice)
- Purple skin splotches or a rash or both
- Small size at birth (or low birth weight)
- Enlarged spleen
- Enlarged and poorly functioning liver
- Pneumonia
- Seizures
- Cytomegalovirus Briefs
- Cytomegalovirus In-Depth
- STI Symptoms
- STI Testing Centers
- List of All STIs/STDs
- Activities That Put You At Risk
- STIs in People with Penises
- STIs in People with Vulvas/Vaginas
References
- Symptoms
- De La Torre-Almaráz, R., V. Pallas, and JESUS ANGEL Sánchez-Navarro. “First report of Cucumber mosaic virus (CMV) and CARNA-5 in carnation in Mexico.” Plant Disease 100.7 (2016): 1509-1509.
- Wong, Yu Jun, et al. “Cytomegalovirus (CMV) hepatitis: an uncommon complication of CMV reactivation in drug reaction with eosinophilia and systemic symptoms.” Singapore medical journal 59.2 (2018): 112.
- Mizukawa, Y., et al. “Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms severity score: A useful tool for assessing disease severity and predicting fatal cytomegalovirus disease.” Journal of the American Academy of Dermatology 80.3 (2019): 670-678.
- Marin, Lauro Juliano, et al. “Prevalence and clinical aspects of CMV congenital Infection in a low-income population.” Virology journal 13.1 (2016): 148.
- Liu, Yingna, et al. “Diagnostic utility of ocular symptoms and vision for cytomegalovirus retinitis.” PloS one 11.10 (2016): e0165564.
- Testing
- Bergevin, Anna, et al. “Cost–benefit analysis of targeted hearing directed early testing for congenital cytomegalovirus infection.” International Journal of pediatric otorhinolaryngology 79.12 (2015): 2090-2093.
- Boeckh, Michael, et al. “Cytomegalovirus (CMV) DNA quantitation in bronchoalveolar lavage fluid from hematopoietic stem cell transplant recipients with CMV pneumonia.” The Journal of infectious diseases 215.10 (2017): 1514-1522.
- Lee, Edward R., and Dylan K. Chan. “Implications of dried blood spot testing for congenital CMV on management of children with hearing loss: A preliminary report.” International journal of pediatric otorhinolaryngology 119 (2019): 10-14.
- Johnson, Jessica, et al. “CMV Disease in IBD: comparison of diagnostic tests and correlation with disease outcome.” Inflammatory bowel diseases 24.7 (2018): 1539-1546.
- Reitter, A., et al. “Incidence of CMV co-infection in HIV-positive women and their neonates in a tertiary referral centre: a cohort study.” Medical microbiology and immunology 205.1 (2016): 63-71.
- Treatment
- Goodman, A. L., et al. “CMV in the gut: a critical review of CMV detection in the immunocompetent host with colitis.” European Journal of Clinical Microbiology & Infectious Diseases 34.1 (2015): 13-18.
- Schulz, Uwe, et al. “CMV immunoglobulins for the treatment of CMV infections in thoracic transplant recipients.” Transplantation 100.Suppl 3 (2016): S5.
- Maffini, Enrico, et al. “Treatment of CMV infection after allogeneic hematopoietic stem cell transplantation.” Expert review of hematology 9.6 (2016): 585-596.
- Maertens, Johan, et al. “Maribavir versus Valganciclovir for preemptive treatment of cytomegalovirus (CMV) viremia: a randomized, dose-ranging, phase 2 study among hematopoietic stem cell transplant (SCT) and solid organ transplant (SOT) recipients.” Open Forum Infectious Diseases. Vol. 3. No. suppl_1. Oxford University Press, 2016.
- Smith, Davey M., et al. “Asymptomatic CMV replication during early human immunodeficiency virus (HIV) infection is associated with lower CD4/CD8 ratio during HIV treatment.” Clinical Infectious Diseases 63.11 (2016): 1517-1524.
- Prevention
- Rawlinson, William D., et al. “Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy.” The Lancet Infectious Diseases 17.6 (2017): e177-e188.
- Revello, Maria Grazia, et al. “Prevention of primary cytomegalovirus infection in pregnancy.” EBioMedicine 2.9 (2015): 1205-1210.
- Fernández‐Ruiz, Mario, et al. “Cytomegalovirus prevention strategies in seropositive kidney transplant recipients: an insight into current clinical practice.” Transplant International 28.9 (2015): 1042-1054.
- Naing, Zin W., et al. “Congenital cytomegalovirus infection in pregnancy: a review of prevalence, clinical features, diagnosis and prevention.” Australian and New Zealand Journal of Obstetrics and Gynaecology 56.1 (2016): 9-18.
- Boeckh, Michael, et al. “Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial.” Annals of internal medicine 162.1 (2015): 1-10.
- Transmission
- AABB, Clinical Transfusion Medicine Committee, et al. “AABB Committee Report: reducing transfusion‐transmitted cytomegalovirus infections.” Transfusion 56.6pt2 (2016): 1581-1587.
- Hamprecht, Klaus, and Rangmar Goelz. “Postnatal cytomegalovirus infection through human milk in preterm infants: Transmission, clinical presentation, and prevention.” Clinics in perinatology 44.1 (2017): 121-130.
- Kagan, Karl Oliver, et al. “Prevention of maternal-fetal transmission of CMV by hyperimmunoglobulin (HIG) administered after a primary maternal CMV infection in early gestation.” Geburtshilfe und Frauenheilkunde 78.10 (2018): FV43.
- Rawlinson, William D., et al. “Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy.” The Lancet Infectious Diseases 17.6 (2017): e177-e188.
- Schleiss, Mark R. “Preventing congenital cytomegalovirus infection: protection to a ‘T’.” Trends in microbiology 24.3 (2016): 170-172.